- Home
- EVMN
EVMN
Evommune Inc.
as of 09-01-2026 4:00pm EST
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 405.2M | IPO Year: | 2025 |
| Target Price: | $43.88 | AVG Volume (30 days): | 445.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.54 | EPS Growth: | 75.23 |
| 52 Week Low/High: | $10.47 - $33.20 | Next Earning Date: | 06-11-2026 |
| Revenue: | $13,000,000 | Revenue Growth: | 85.71% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -8.22 | Index: | N/A |
| Free Cash Flow: | -76676000.0 | FCF Growth: | N/A |
AI-Powered EVMN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2026 Q2 Q2 2026 Earnings
8-K Aug 6, 2026
Q2 2026 Earnings
8-KAug 6, 2026
2026 Q1 Q1 2026 Earnings
8-K May 7, 2026
Q1 2026 Earnings
8-KMay 7, 2026
2025 Q4 Q4 2025 Earnings
8-K Mar 5, 2026
Q4 2025 Earnings
8-KMar 5, 2026
Compare EVMN vs Leading Stocks
See how EVMN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EVMN Evommune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.